Pivotal Investment Corp III (PICC)


Stock Price Forecast

March 29, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Pivotal Investment Corp III chart...

About the Company

We do not have any company description for Pivotal Investment Corp III at the moment.

Employees

3

Exchange

OTC MARKETS

$M

Total Revenue

3

Employees

$343M

Market Capitalization

18.49

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PICC News

Pivotal Investment Corporation III Redeemable Warrants each whole warrant exercisable for shares of (PICCW)

1mon ago, source: Nasdaq

Please note that the dividend history might include the company’s preferred securities as well. Price/Earnings Ratio is a widely used stock evaluation measure. For a security, the Price ...

The Pivotal Role Of Private Capital In A Post-War Economy

2d ago, source:

Ultimately, capital from all sectors will be needed to assist in the post-war recovery in Ukraine, Gaza and Israel.

Women VCs Revolutionize Funding For Enterprise AI Software

14d ago, source:

Sheila Gulati and Stacey Giard of Tola Capital—promote diversity among LPs and fuel innovation through early-stage ...

How Olema Oncology moved from layoffs to pivotal cancer drug studies

14d ago, source:

A drug developer that cut a quarter of its workforce last year is now hiring as it plans to push a second drug into clinical ...

Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals

1mon ago, source: Hosted on MSN

Aquestive Therapeutics, Inc. AQST shares jumped 16% on Mar 15 after the company achieved the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of ...

Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug

5d ago, source:

Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain ...

Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

1d ago, source:

Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for ...

ONWARD Medical NV: ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date

44m ago, source:

EX® System Successfully raised EUR 20M in equity capital Announced positive top-line results from Up-LIFT pivotal study Forged partnership to provide ...

Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%

1mon ago, source: Nasdaq

Shares of Amylyx Pharmaceuticals AMLX nosedived 82.2% on Mar 8 after management announced topline results from the phase III PHOENIX study ... leaving the company without a marketed drug and ...

ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date

5h ago, source: Yahoo Finance

This additional research site prepares the Company for expected Q4 2024 initiation of a global pivotal trial called Empower BP to ... Equity research analysts from 5 investment banks now cover ONWARD, ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...